Safety Shot Announces Clinical Trial Results Demonstrating Its Dietary Supplement Significantly Reduces Blood Alcohol Content
Portfolio Pulse from Benzinga Newsdesk
Safety Shot announced clinical trial results showing its dietary supplement significantly reduces blood alcohol content (BAC). Participants experienced a 30%-50% faster reduction in BAC compared to a placebo, with measurable drops continuing in successive 30-minute increments.
August 12, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Safety Shot's clinical trial results demonstrate a significant reduction in blood alcohol content (BAC) with its dietary supplement. Participants experienced a 30%-50% faster reduction in BAC compared to a placebo, indicating strong efficacy of the product.
The clinical trial results are highly positive, showing significant efficacy of Safety Shot's product in reducing BAC. This could lead to increased consumer interest and sales, positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100